Back | Next |
home / stock / myov / myov message board
Subject | By | Source | When |
---|---|---|---|
I believe they want to be taken over | Dallas-Cowboys | investorshub | 09/30/2022 9:21:05 AM |
Either way they are going to make a | Cosa | investorshub | 09/30/2022 4:09:40 AM |
Yes Sumo owns 53% and has 3 board | Dallas-Cowboys | investorshub | 09/13/2022 10:38:53 PM |
With Sumitomo owning the majority of shares it | Cosa | investorshub | 09/13/2022 7:09:18 PM |
With their share count at around 100 million | Dallas-Cowboys | investorshub | 09/12/2022 12:53:14 AM |
So you are looking for a BO at | rosemountbomber | investorshub | 09/12/2022 12:25:03 AM |
Yes Sumo owns majority and some people think | Dallas-Cowboys | investorshub | 09/09/2022 7:58:56 PM |
Sumitomo owns most of the shares, so there | Cosa | investorshub | 09/09/2022 7:41:26 PM |
Took a little more off the table today. | Cosa | investorshub | 09/09/2022 7:31:31 PM |
Listened to the conference yesterday seemed run of | Dallas-Cowboys | investorshub | 09/09/2022 2:40:12 PM |
Difficult to believe we wouldn't see 52 week | rosemountbomber | investorshub | 09/08/2022 9:34:21 PM |
Nice break to the upside! | Cosa | investorshub | 09/08/2022 6:01:28 PM |
Consolidating the past few weeks. Which way | Cosa | investorshub | 09/07/2022 9:13:43 AM |
Took some profits today. Looking really bulllish! | Cosa | investorshub | 08/12/2022 6:08:40 PM |
Any guess as to what to expect in | rosemountbomber | investorshub | 08/06/2022 10:50:18 AM |
MYFEMBREE FDA Approved! Looking forward to Monday! | Cosa | investorshub | 08/06/2022 3:56:30 AM |
Those bargain prices from a few months back | Cosa | investorshub | 08/04/2022 7:22:03 PM |
Up and to the right. | Cosa | investorshub | 07/27/2022 8:50:57 PM |
If volume comes back this will blast off. | Cosa | investorshub | 06/23/2022 8:20:31 PM |
Go baby go!! $MYOV! Going up on | Cosa | investorshub | 06/07/2022 6:35:27 PM |
News, Short Squeeze, Breakout and More Instantly...
Myovant Sciences Ltd. Company Name:
MYOV Stock Symbol:
NYSE Market:
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...